Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00390806 · ClinicalTrials.gov registry record · Phase 3
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 472
- Enrollment target
- 20
- Study locations
NCT00390806: Completed Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
NCT00390806 is a Phase 3 study of Lung Cancer, Non-Small Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 472 participants, above the 426-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00390806, a Phase 3 study of Lung Cancer, Non-Small Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 472 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition.
Primary Outcome
Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG HYCAMTIN, oral capsules
Study Locations (20)
Illinois
- GSK Investigational Site - Chicago
- GSK Investigational Site - Elk Grove Village
- GSK Investigational Site - Galesburg
- GSK Investigational Site - Park Ridge
- GSK Investigational Site - Rockford
- GSK Investigational Site - Skokie
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Duarte
- GSK Investigational Site - Pleasant Hill
Florida
- GSK Investigational Site - Lakeland
- GSK Investigational Site - Tampa
- GSK Investigational Site - Tampa
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Glendale
Arkansas
- GSK Investigational Site - Hot Springs
Colorado
- GSK Investigational Site - Aurora
Indiana
- GSK Investigational Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 472 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
What the finished NCT00390806 record still lists
NCT00390806 is an interventional study that assigns participants to a tested intervention. The registered 472 participants enrollment target is mid-sized for trials with a published cap, above the 426-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT00390806 names 20 study sites across 11 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00390806 about?
NCT00390806 is a clinical study titled "Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer". The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiat...
What is the current status of trial NCT00390806?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 472 participants. The study started on 2006-12. Estimated completion is 2013-09.
What conditions does trial NCT00390806 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT00390806?
The interventions under investigation include: Radiation (RADIATION), HYCAMTIN, oral capsules (DRUG).
Who is sponsoring clinical trial NCT00390806?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00390806 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00390806's enrollment target sits among peer trials
472 5th of 16 higher than 12 of 16 other Lung Cancer, Non-Small Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
- NCT07199517 · 472 participants · NA
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
- NCT07225881 · 472 participants · NA
Eatwell Clinical Trial (R01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia